Forendo Pharma which is a drug development company developing novel oral treatments for endometriosis patients asserted the appointment of David Colpman as a Non-executive Director to its Board of Directors.
David brings on board 25 years of experience in pharma and biotech business development and strategy. His previous roles include Head of Global Business Development at Shire and business development and commercial positions at Glaxo Wellcome and Novo Nordisk. David has a degree in Pharmacy and he also serves on the Boards of Orexo AB and HRA Pharma Ltd.
The key distinctiveness of the company’s lead HSD17B1 inhibitor, FOR-6219, compared to other drug treatments in the market or in clinical development is the ability to act locally without impacting the systemic estrogen levels, as demonstrated in preclinical models. Forendo’s first in class compound with selective activity is expected to allow safer long-term treatment of this chronic disease without harmful symptoms of estrogen deficiency, that are seen with current treatment options for endometriosis. The company’s lead program is entering phase I studies in 2018.
David Colpman says “I am very excited to join the Forendo Board. The company is developing a truly novel therapy, for the large unmet needs of this disease, that affects as many as 10% of all women in reproductive age.”
Risto Lammintausta, CEO of Forendo Pharma said “His insights and expertise will be very helpful as we continue to evaluate the commercial alternatives of our programs.”